2023 World Conference on Lung Cancer (Posters)-P2.16. Sintilimab in Combination With Carboplatin/Cisplatin and Etoposide in the Treatment of Patients with Previously Untreated ES-SCLC

P2.16. Sintilimab in Combination With Carboplatin/Cisplatin and Etoposide in the Treatment of Patients with Previously Untreated ES-SCLC - PDF(Slides)

Back to course

Pdf Summary

This document discusses a study on the use of Sintilimab in combination with Carboplatin/Cisplatin and Etoposide for the treatment of patients with previously untreated extensive-stage small cell lung cancer (ES-SCLC). The study aims to evaluate the progression-free survival (PFS) rate, overall survival (OS), and overall response rate (ORR) of the treatment, as well as the quality of life of the patients. The study is a single-center, single-arm, investigator-initiated phase study. The eligibility criteria include age between 18 and 75, previously untreated histologically/cytologically confirmed ES-SCLC, Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2, measurable disease, and adequate organ function. Patients who meet the criteria will receive Sintilimab, Carboplatin/Cisplatin, and Etoposide until disease progression or unacceptable toxicity. The study also includes an exploratory assessment of blood/tumor tissue for potential biomarkers. Adverse events will be monitored and graded throughout the trial. The study is ongoing, with enrollment beginning in August 2021. Small cell lung cancer is an aggressive form of cancer with limited treatment options. Immunotherapy has shown promise in the treatment of SCLC, and Sintilimab, an anti-PD-1 antibody, is currently the standard therapy for advanced non-small cell lung cancer in China. The role of Sintilimab in ES-SCLC is being further explored. The study is sponsored by Shanghai Pulmonary Hospital and Innovent Biologics, Inc.

Asset Subtitle

Mengqing Xie

Meta Tag

Speaker Mengqing Xie

Topic SCLC & Neuroendocrine Tumors: Trials in Progress

Keywords

Sintilimab

Carboplatin

Cisplatin

Etoposide

extensive-stage small cell lung cancer

progression-free survival

overall survival

overall response rate

quality of life

single-center study